Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T)

Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T)

Objective: We purpose to confirm the effect of teneligliptin (Tenelia), a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, on glycemic control and non-glucose risk factors for macroangiopathy, including blood pressure, lipid metabolism, and body weight. Methods: In a prospective, multicenter, ope...

Full description

Bibliographic Details
Main Authors: Yosuke Takamiya, Keisuke Okamura, Kazuyuki Shirai, Tetsu Okuda, Kunihisa Kobayashi, Hidenori Urata
Format: Article
Language:English
Published: Taylor & Francis Group 2020-04-01
Series:Clinical and Experimental Hypertension
Subjects:
teneligliptin
dipeptidyl peptidase-4 inhibitor
glycemic control
hypotensive effect
safety
Online Access:http://dx.doi.org/10.1080/10641963.2019.1601207

Internet

http://dx.doi.org/10.1080/10641963.2019.1601207

Similar Items